Antibiotics (Feb 2023)

Meropenem Model-Informed Precision Dosing in the Treatment of Critically Ill Patients: Can We Use It?

  • Letao Li,
  • Sebastiaan D. T. Sassen,
  • Tim M. J. Ewoldt,
  • Alan Abdulla,
  • Nicole G. M. Hunfeld,
  • Anouk E. Muller,
  • Brenda C. M. de Winter,
  • Henrik Endeman,
  • Birgit C. P. Koch

DOI
https://doi.org/10.3390/antibiotics12020383
Journal volume & issue
Vol. 12, no. 2
p. 383

Abstract

Read online

The number of pharmacokinetic (PK) models of meropenem is increasing. However, the daily role of these PK models in the clinic remains unclear, especially for critically ill patients. Therefore, we evaluated the published meropenem models on real-world ICU data to assess their suitability for use in clinical practice. All models were built in NONMEM and evaluated using prediction and simulation-based diagnostics for the ability to predict the subsequent meropenem concentrations without plasma concentrations (a priori), and with plasma concentrations (a posteriori), for use in therapeutic drug monitoring (TDM). Eighteen PopPK models were included for evaluation. The a priori fit of the models, without the use of plasma concentrations, was poor, with a prediction error (PE)% of the interquartile range (IQR) exceeding the ±30% threshold. The fit improved when one to three concentrations were used to improve model predictions for TDM purposes. Two models were in the acceptable range with an IQR PE% within ±30%, when two or three concentrations were used. The role of PK models to determine the starting dose of meropenem in this population seems limited. However, certain models might be suitable for TDM-based dose adjustment using two to three plasma concentrations.

Keywords